title: Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma.
abstract: Twenty-one patients with advanced refractory myeloma (nine primary unresponsive to melphalan, 12 relapsed and resistant to first-line salvage therapy) received monthly 7 d courses of cyclophosphamide by continuous infusion, associated with teniposide and dexamethasone. Six patients died within 2 months from start of treatment, before receiving an adequate trial. Among the 15 evaluable patients, there were eight objective responses and three improvements (decrease of monoclonal protein greater than 50% or greater than 30%, respectively). After a median follow-up of 10 months, all responding patients are alive and none of them is still relapsed. In heavily pretreated patients, ineligible for more aggressive approaches, cyclophosphamide by continuous-infusion exerted a good antineoplastic activity without increasing toxicity.
authors.affiliation: Department of Haematology, University of Florence, Firenze, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Leoni
authors.forename: S
authors.initials: S
authors.lastname: Ciolli
authors.forename: F
authors.initials: F
authors.lastname: Salti
authors.forename: P
authors.initials: P
authors.lastname: Teodori
authors.forename: P R
authors.initials: PR
authors.lastname: Ferrini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D013713:Teniposide / Q000008:administration & dosage
chemical_list: D003907:Dexamethasone; D003520:Cyclophosphamide; D013713:Teniposide